Abdelaal, Ahmed M. http://orcid.org/0000-0002-4698-3220
Sohal, Ikjot S. http://orcid.org/0000-0003-0118-6129
Iyer, Shreyas http://orcid.org/0009-0006-7081-4116
Sudarshan, Kasireddy
Kothandaraman, Harish
Lanman, Nadia A. http://orcid.org/0000-0002-1819-7070
Low, Philip S.
Kasinski, Andrea L. http://orcid.org/0000-0002-9602-7827
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA205420, R01CA226259, P30CA023168)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Defense (W81XWH-22-1-1085, PC200139)
Article History
Received: 8 June 2023
Revised: 25 July 2023
Accepted: 28 July 2023
First Online: 5 September 2023
Competing interests
: ALK and PSL are inventors on U.S. patent US20190298843A1 submitted by Purdue University that covers methods and uses of ligand-targeted delivery of miRNAs. ALK, AMA, and ISS are inventors on U.S. provisional patent 70078-01 submitted by Purdue University that covers methods and uses of modified miR-34a. The remaining authors declare that they have no competing interests.